| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 11, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2025 | $35.00 | Neutral → Buy | H.C. Wainwright |
| 7/14/2025 | Outperform → Mkt Perform | William Blair | |
| 1/24/2022 | $24.00 → $10.00 | Buy | B. Riley Securities |
| 11/9/2021 | $24.00 | Buy | B. Riley Securities |
| 11/9/2021 | $26.00 | Outperform | Robert W. Baird |
| 11/9/2021 | Outperform | William Blair | |
| 11/9/2021 | $30.00 | Outperform | Evercore ISI Group |
| 11/9/2021 | $26.00 | Outperform | Baird |
4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2026 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for gu
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.
First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class immune therapy for critical illness where there are no approved mortality-reducing therapiesPreliminary data expected in the second half of 2026 NEW YORK and LVIV, Ukraine, May 28, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic iNKT cell therapies for cancer and immune disorders, today announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 wi
H.C. Wainwright upgraded MiNK Therapeutics from Neutral to Buy and set a new price target of $35.00
William Blair downgraded MiNK Therapeutics from Outperform to Mkt Perform
B. Riley Securities reiterated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $10.00 from $24.00 previously
4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)
10-Q - MiNK Therapeutics, Inc. (0001840229) (Filer)
8-K - MiNK Therapeutics, Inc. (0001840229) (Filer)
DEF 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having served 23 years in the U.S. Army, including as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. He pioneered major innovations in combat casualty care, transfusion medicine, and trauma systems design that saved countless lives and reshaped global health protocol
Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. Dr. Hammond is a nationally recognized leader in pulmonary and critical care medicine with extensive experience advancing registration-stage programs in severe pulmonary and inflammatory diseases. She has served as principal inves
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics ((MiNK, NASDAQ:INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases. Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung diseaseNon-dilutive collaborations expand MiNK's platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programsCompany continues disciplined execution with reduced operating burn and focused advancement of high-priority programsNew clinical data to be presented at the ATS conference on May 20, 2026 NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, I
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the first quarter ended March 31, 2026, before the market opens on Friday, May 15, 2026. The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update on recent progress across its iNKT cell therapy platform, including clinical development, translational research, platform expansion, and strategic initiatives. The update will
ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncologyNIH STTR grant and Mary Gooze philanthropic award fully fund graft-versus-host disease (GVHD) preclinical data with clinical trial launch in 1H 2026Keystone Symposia data report iNKT depletion in end-stage Pulmonary Fibrosis (IPF); underscores pipeline expansionPortfolio focused on high-value immune restoration with multiple 2026 clinical catalysts NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT),
SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)
SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)
SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)